Shin-Ae Kim1, Jong-Lyel Roh2, Sung-Bae Kim3, Seung-Ho Choi1, Soon Yuhl Nam1, Sang Yoon Kim1. 1. Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. 2. Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. rohjl@amc.seoul.kr. 3. Department of Internal Medicine (Oncology), Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Abstract
BACKGROUND: Acetylsalicylic acid (aspirin) and non-steroidal anti-inflammatory drugs (NSAIDs) have been associated with reduced risks for certain human cancers. However, the effects of aspirin and NSAIDs on head and neck squamous cell carcinoma (HNSCC) remain controversial, and the prognostic effects of these drugs in patients with HNSCC are largely unknown. This study examined the clinical impact of aspirin and NSAIDs on disease recurrence and survival in patients with HNSCC. METHODS: This study analysed a cohort of 1392 consecutive patients who received definitive treatment for previously untreated HNSCC at our tertiary referral center. Aspirin or NSAID use was considered positive if the patients were receiving aspirin or NSAID medication from HNSCC diagnosis to at least 1 year after treatment initiation. Cox proportional hazard models were utilised to determine the association of aspirin and/or NSAID use with recurrence, survival, and second primary cancer occurrence. RESULTS: Of 1392 patients, 81 (5.8%) and 89 (6.4%) received post-diagnosis treatment with aspirin and NSAIDs, respectively. After controlling for clinical factors, aspirin and NSAIDs were not significantly associated with recurrence, survival, or second cancer occurrence (P > 0.05). The cumulative dose of aspirin or NSAIDs did not alter survival outcomes (P > 0.05). CONCLUSION: Our data illustrated that the use of aspirin or NSAIDs has no effect on survival or recurrence in patients with HNSCC.
BACKGROUND:Acetylsalicylic acid (aspirin) and non-steroidal anti-inflammatory drugs (NSAIDs) have been associated with reduced risks for certain humancancers. However, the effects of aspirin and NSAIDs on head and neck squamous cell carcinoma (HNSCC) remain controversial, and the prognostic effects of these drugs in patients with HNSCC are largely unknown. This study examined the clinical impact of aspirin and NSAIDs on disease recurrence and survival in patients with HNSCC. METHODS: This study analysed a cohort of 1392 consecutive patients who received definitive treatment for previously untreated HNSCC at our tertiary referral center. Aspirin or NSAID use was considered positive if the patients were receiving aspirin or NSAID medication from HNSCC diagnosis to at least 1 year after treatment initiation. Cox proportional hazard models were utilised to determine the association of aspirin and/or NSAID use with recurrence, survival, and second primary cancer occurrence. RESULTS: Of 1392 patients, 81 (5.8%) and 89 (6.4%) received post-diagnosis treatment with aspirin and NSAIDs, respectively. After controlling for clinical factors, aspirin and NSAIDs were not significantly associated with recurrence, survival, or second cancer occurrence (P > 0.05). The cumulative dose of aspirin or NSAIDs did not alter survival outcomes (P > 0.05). CONCLUSION: Our data illustrated that the use of aspirin or NSAIDs has no effect on survival or recurrence in patients with HNSCC.
Entities:
Keywords:
Aspirin; Head and neck squamous cell carcinoma; Non-steroidal anti-inflammatory drug; Recurrence; Survival
Authors: Paul M Ridker; Nancy R Cook; I-Min Lee; David Gordon; J Michael Gaziano; Joann E Manson; Charles H Hennekens; Julie E Buring Journal: N Engl J Med Date: 2005-03-07 Impact factor: 91.245
Authors: E Bastiaannet; K Sampieri; O M Dekkers; A J M de Craen; M P P van Herk-Sukel; V Lemmens; C B M van den Broek; J W Coebergh; R M C Herings; C J H van de Velde; R Fodde; G J Liefers Journal: Br J Cancer Date: 2012-03-27 Impact factor: 7.640
Authors: Austin J Iovoli; Gregory M Hermann; Sung Jun Ma; Alexis J Platek; Mark K Farrugia; Edwin Yau; Kimberly E Wooten; Hassan Arshad; Vishal Gupta; Moni A Kuriakose; Wesley L Hicks; Anurag K Singh Journal: JAMA Netw Open Date: 2020-06-01
Authors: Peter C Elwood; Janet E Pickering; Gareth Morgan; Julieta Galante; Alison L Weightman; Delyth Morris; Marcus Longley; Malcolm Mason; Richard Adams; Sunil Dolwani; John Chia W K; Angel Lanas Journal: PLoS One Date: 2018-09-25 Impact factor: 3.240
Authors: Matthew L Hedberg; Noah D Peyser; Julie E Bauman; William E Gooding; Hua Li; Neil E Bhola; Tian Ran Zhu; Yan Zeng; Toni M Brand; Mi-Ok Kim; Richard C K Jordan; Scott VandenBerg; Victor Olivas; Trever G Bivona; Simion I Chiosea; Lin Wang; Gordon B Mills; Jonas T Johnson; Umamaheswar Duvvuri; Robert L Ferris; Patrick Ha; Daniel E Johnson; Jennifer R Grandis Journal: J Exp Med Date: 2019-01-25 Impact factor: 14.307